期刊文献+

肺腺癌细胞S100A6基因siRNA慢病毒载体构建及鉴定 被引量:1

Construction and identification of lent viral vector of siRNA specific for S100A6 gene
下载PDF
导出
摘要 目的:构建肺腺癌细胞S100A6基因siRNA慢病毒载体并鉴定。方法:慢病毒载体(pL enR-GPH)构建靶向S100A6基因的RNA干扰重组体,用以建立S100A6基因稳定沉默的肺腺癌A549细胞株。结果:PCR鉴定结果显示3个扩增的阳性片段均已插入pL enR-GPH载体,测序结果证实三个重组慢病毒载体SH1、SH2、SH3的插入序列完全正确,重组慢病毒载体转染到293T细胞中包装成病毒颗粒,将其感染肺癌A549细胞后,RT-PCR和Western blot检测结果均证实三组重组体感染的细胞内S100A6 mRNA和蛋白的表达受到不同程度的抑制,沉默效率分别为98.29%、84.05%及78.24%。结论:成功构建了S100A6基因RNAi慢病毒重组载体,并建立了其稳定表达的肺腺癌A549细胞株,为探讨S100A6基因对肺腺癌生物学行为的影响提供了可靠的细胞模型。 Objective:To construct a recombinant mediating RNA interference(RNAi)against S100A6 gene and identify.Methods:The lentiviral vector was used for construction of a recombinant mediating RNA interference(RNAi) against S100A6 gene.Recombinant vector plasmid was transfected into non -small cell lung cancer (NSCLC)A549 cells by liposome.Results:Three amplified positive fragments were inserted into pLenR -GPH vectors.DNA sequencing re-sults showed that the 3 recombinant lentiviralplasmids,SH1 /SH2 /SH3 were constructed successfully.After transfec-tion with A549 cells by liposome,RT -PCR and Western blot analysis confirmed that the expression of S100A6 mRNAand protein was inhibited in the 3 recombinant lentiviral plasmids transfected groups,and gene silencing efficacy was 98.29%,84.05% and 78.24%,respectively.Conclusion:The lentiviral vector of RNAi targeting S100A6 gene was successfully constructed,and NSCLC A549 stable cell line with S100A6 gene knockdown was established.This study finally provided a new cell model to explore the biological behavior of the S100A6 gene in NSCLC A549 cells.
出处 《现代肿瘤医学》 CAS 2015年第20期2907-2912,共6页 Journal of Modern Oncology
基金 国家自然科学基金资助项目(编号:81001040) 第四军医大学优秀文职人员基金(编号:2011-01) 第四军医大学唐都医院后备人才基金(编号:5033)
关键词 S100A6基因 siRNA慢病毒载体 RNA干扰 A549细胞 S100A6 gene,siRNA lentiviral vector,RNA intervene,A549 cell
  • 相关文献

参考文献11

  • 1YangSY.Thestatusquo,confusionandprospectofearlydiagnosisforlungcancer[J].JXi'anJiaotongUniversity(MedicalScience),2011,32(1):1-5.
  • 2NanYD,JinFG,YangSY,etal.Discoveryofasetofbiomarkersofhumanlungadenocarcinomathroughcell-mapproteomicsandbioinformatics[J].MedOncol,2010,27:1398-1406.
  • 3ZhaoS,DongWB,ZhangC,etal.Theinterferenceeffectoflentivi-ralmediatedshRNAontheexpressionofPin1inA549cells[J].ChinJCellMolImmunol,2014,30(3):245-249.
  • 4WangWY,ZhaoGQ,ZhouY,etal.ConstructionandidentificationoflentiviralvectorofsiRNAspecificforbeclin1gene[J].JBio-medicalEngineering,2013,30(01):131-135.
  • 5MiaoJK,ZhouL.ProgressoftranscriptionalregulationofS100A6anditsrelationswithtumor[J].JChongqingMedicalUniversity,2007,32(7):779-781.
  • 6ZhangH,ChenJ,SunB,etal.SpecificexpressionofosteopontinandS100A6inhepatocellularcarcinoma[J].Surgery,2011,149(6):783-791.
  • 7WeiBR,HooverSB,RossMM,etal.SerumS100A6concentrationpredictsperitonealtumorburdeninmicewithepithelialovariancancerandisassociatedwithadvancedstageinpatients[J].PLoSOne,2009,4(10):e7670.
  • 8MaelandsmoGM,FlrenesVA,MellingsaeterT,etal.DifferentialexpressionpatternsofS100A2,S100A4andS100A6duringpro-gressionofhumanmalignantmelanoma[J].IntJCancer,1997,74(4):464-469.
  • 9IshiiA,SuzukiM,SatomiK,etal.IncreasedcytoplasmicS100A6expressionisassociatedwithpulmonaryadenocarcinomaprogression[J].PatholInt,2009,59(9):623-630.
  • 10GavrilovK,SaltzmanWM.TherapeuticsiRNA:Principles,chal-lenges,andstrategies[J].YaleJBiolMed,2012,85(2):187-200.

同被引文献9

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部